Zimmer Biomet Enters Partnership To Improve Outcomes For Patients With Fragile Hip Fractures

 
• By Marion Webb

Zimmer Biomet announced today it entered into a partnership with the European Pathway Association, a not-for-profit group that evaluates care pathways, to study patients with fragile hip fractures, understand the care process, and improve outcomes.

Crutches

Zimmer Biomet Holdings Inc. announced today it joined forces with the European Pathway Association (EPA), an international not-for-profit group, made up of academic institutions, clinical/care pathway networks and user groups evaluating and implementing care pathways, to launch a study looking at key aspects of hip fragility in fracture care.

The goal is to better understand the care process and help improve the quality, efficiency, and outcomes of care pathways for patients with fragile hip fractures through Zimmer Biomet's Rapid...

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.